Clinical management of uterine papillary serous carcinoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 1, 2011, Pages 71-81

  Roelofsen, Thijs ^a   Van Ham, Maaike A ^a   De Hullu, Joanne A ^a   Massuger, Leon F ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

comprehensive surgical staging; cytoreductive surgery; endometrial cancer; papillary serous carcinoma; radiation therapy; uterine chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE;

BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; HUMAN; HYSTERECTOMY; OVARIECTOMY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE PAPILLARY SEROUS CARCINOMA; UTERUS BIOPSY; UTERUS CANCER; UTERUS CARCINOMA;

ANTINEOPLASTIC PROTOCOLS; CARCINOMA, PAPILLARY; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MEDICATION THERAPY MANAGEMENT; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 78650485259     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.199     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15(1), 10-17 (1983).
3. Fox H. Endometrial carcinogenesis and its relation to oestrogens. Pathol. Res. Pract. 179(1), 13-19 (1984).
4. Sivridis E, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. Virchows Arch. 439(2), 118-126 (2001).
5. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv. Anat. Pathol. 11(3), 117-142 (2004).
6. Goff BA. Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol. Oncol. 98(3), 341-343 (2005).
7. Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr. Opin. Obstet. Gynecol. 20(1), 26-33 (2008).
8. Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol. Oncol. 81(1), 92-99 (2001).
9. Cirisano FD Jr, Robboy SJ, Dodge RK et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol. Oncol. 77(1), 55-65 (2000).
10. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin. Obstet. Gynecol. 39(3), 686-695 (1996).
11. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic signifcance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol. Oncol. 47(3), 298-305 (1992).
12. Grice J, Ek M, Greer B et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol. Oncol. 69(1), 69-73 (1998).
13. Trope C, Kristensen GB, Abeler VM. Clear-cell and papillary serous cancer: treatment options. Best Pract. Res. Clin. Obstet. Gynaecol. 15(3), 433-446 (2001).
14. Kato DT, Ferry JA, Goodman A et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol. Oncol. 59(3), 384-389 (1995).
15. Piura B, Meirovitz M, Shmulman M, Yanai-Inbar I, Cohen Y, Dgani R. Uterine papillary serous carcinoma: study of 19 cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 79(1), 69-73 (1998).
16. Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I-III) disease. Gynecol. Oncol. 81(2), 279-286 (2001).
17. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol. Oncol. 95(3), 593-596 (2004).
18. Slomovitz BM, Burke T W, Eifel PJ et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol. Oncol. 91(3), 463-469 (2003).
19. Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma Gynecol. Oncol. 74(3), 465-467 (1999).
20. Amant F, Cadron I, Fuso L et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol. Oncol. 98(2), 274-280 (2005).
21. Cirisano FD Jr, Robboy SJ, Dodge RK et al. Epidemiologic and surgicopathologic fndings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol. Oncol. 74(3), 385-394 (1999).
22. Gehrig PA, Groben PA, Fowler WC Jr, Walton LA, Van LL. Noninvasive papillary serous carcinoma of the endometrium. Obstet. Gynecol. 97(1), 153-157 (2001).
23. Dunton CJ, Balsara G, McFarland M, Hernandez E. Uterine papillary serous carcinoma: a review. Obstet. Gynecol. Surv. 46(2), 97-102 (1991).
24. Sood BM, Jones J, Gupta S et al. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 57(1), 208-216 (2003).
25. Fader AN, Nagel C, Axtell AE et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol. Oncol. 112(3), 558-562 (2009).
26. Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol. Oncol. 54(3), 264-268 (1994).
27. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6(2) 93-108 (1982).
28. Goldberg H, Miller RC, Bdah-Bortnyak R et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol. Oncol. 108(2), 298-305 (2008).
29. Fader AN, Starks D, Gehrig PA et al An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 115(2), 244-248 (2009).
30. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol. 16(6), 600-610 (1992).
31. Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int. J. Gynecol. Cancer 16(3), 972-978 (2006).
32. Hamilton CA, Cheung MK, Osann K et al. The effect of adjuvant chemotherapy versus whole ab domino pelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol. Oncol. 103(2), 679-683 (2006).
33. Kelly MG, O'Malley DM, Hui P et al Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol. 98(3), 353-359 (2005).
34. Schwartz PE. The management of serous papillary uterine cancer. Curr. Opin. Oncol. 18(5), 494-499 (2006).
35. Memarzadeh S, Holschneider CH, Bristow RE et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int. J. Gynecol. Cancer 12(5), 454-458 (2002).
36. Hamilton CA, Liou WS, Osann K et al Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int. J. Radiat. Oncol Biol. Phys. 63(3), 839-844 (2005).
37. Chan JK, Loizzi V, Youssef M et al Signifcance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 90(1), 181-185 (2003).
38. 192Ir) and chemotherapy. Int. J. Radiat. Oncol. Biol Phys. 40(1), 77-84 (1998).
39. Gehrig PA, Van LL, Fowler WC. The role of omentectomy during the surgical staging of uterine serous carcinoma. Int. J. Gynecol Cancer 13(2), 212-215 (2003).
40. Thomas MB, Mariani A, Cliby WA et al Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol. Oncol. 107(2), 186-189 (2007).
41. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170(4), 974-979 (1994).
42. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 71, 1534-1540 (1999).
43. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol. 55, S91-S96 (1994).
44. O'Hanlan KA, Levine PA, Harbatkin D et al. Virulence of papillary endometrial carcinoma. Gynecol. Oncol. 37(1), 112-119 (1990).
45. Wang W, DO V, Hogg R et al. Uterine papillary serous carcinoma: patterns of failure and survival. Aust. N. Z. J. Obstet. Gynaecol. 49(4), 419-425 (2009).
46. Thomas MB, Mariani A, Cliby WA et al Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol. Oncol. 107(2), 190-193 (2007).
47. Sutton GP, Brill L, Michael H, Stehman FB, Ehrlich CE. Malignant papillary lesions of the endometrium. Gynecol. Oncol. 27(3), 294-304 (1987).
48. Smith RS, Kapp DS, Chen Q, Teng NN. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 48(3), 767-778 (2000).
49. Gallion HH, van Nagell JR Jr, Powell DF et al. Stage I serous papillary carcinoma of the endometrium. Cancer 63(11), 2224-2228 (1989).
50. Frank AH, Tseng PC, Haffty BG et al. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer 68(7), 1516-1519 (1991).
51. Elit L, Kwon J, Bentley J et al. Optimal management for surgically stage 1 serous cancer of the uterus. Gynecol. Oncol. 92(1), 240-246 (2004).
52. Huh WK, Powell M, Leath CA et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol. Oncol. 91(3), 470-475 (2003).
53. Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 57(4), 1004-1009 (2003). (Pubitemid 37324118)
54. Sutton G, Axelrod JH, Bundy BN et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol. Oncol. 97(3), 755-763 (2005).
55. Sutton G, Axelrod JH, Bundy BN et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 100(2), 349-354 (2006).
56. Dubeshter B, Estler K, Altobelli K et al. High-dose rate brachytherapy for stage I/II papillary serous or clear cell endometrial cancer. Gynecol. Oncol. 94(2), 383-386 (2004).
57. Low JS, Wong EH, Tan HS et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 97(1), 171-177 (2005).
58. 32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a Phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol. Oncol. 96(3), 818-823 (2005).
59. Havrilesky LJ, Secord AA, Bae-Jump V et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol. Oncol. 105(3), 677-682 (2007).
60. Alektiar KM, Makker V, Bu-Rustum NR et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecol. Oncol. 112(1), 142-145 (2009).
61. Mallipeddi P, Kapp DS, Teng NN. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer 71(10), 3076-3081 (1993).
62. Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible beneft to patients with stage I uterine papillary cancer. Gynecol. Oncol. 48(1), 32-37 (1993).
63. Levenback C, Burke TW, Silva E et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol. Oncol 46(3), 317-321 (1992).
64. Price FV, Chambers SK, Carcangiu ML et al. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 51(3), 383-389 (1993).
65. Chambers JT, Chambers SK, Kohorn EI, Carcangiu ML, Schwartz PE. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol. Oncol. 60(3), 438-442 (1996).
66. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 74(2), 272-277 (1999).
67. Bancher-Todesca D, Neunteufel W, Williams KE et al. Infuence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol. Oncol. 71(3), 344-347 (1998).
68. Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma. A clinical study. Cancer 75(9), 2239-2243 (1995).
69. Smith MR, Peters WA III, Drescher CW Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am. J. Obstet. Gynecol. 170(6), 1677-1681 (1994).
70. Fitzgerald D, Rosenthal S. Uterine papillary serous carcinoma. Complete response to combination chemotherapy. Cancer 56(5), 1023-1024 (1985).
71. Resnik E, Taxy JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 62(1), 123-127 (1996).
72. Ramondetta L, Burke TW, Levenback C et al. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol. Oncol. 82(1), 156-161 (2001). (Pubitemid 32634969)
73. Fader AN, Drake RD, O'Malley DM et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115(10), 2119-2127 (2009).
74. Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL. Pilot phase II trial of radiation 'sandwiched' between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 108(1), 201-206 (2008).
75. Alektiar KM, Makker V, Bu-Rustum NR et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecol. Oncol. 112(1), 142-145 (2009).
76. Dietrich CS, Modesitt SC, DePriest PD et al. The effcacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 99(3), 557-563 (2005).
77. Lim P, Al KA, Gilks B, Wong F, Aquino-Parsons C. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 91(4), 752-757 (2001).
78. Kwon JS, Abrams J, Sugimoto A, Carey MS. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? Int. J. Gynecol. Cancer 18(4), 820-824 (2008).
79. Nguyen NP, Sallah S, Karlsson U et al. Prognosis for papillary serous carcinoma of the endometrium after surgical staging. Int. J. Gynecol. Cancer 11(4), 305-311 (2001).
80. Martin JD, Gilks B, Lim P. Papillary serous carcinoma -a less radio-sensitive subtype of endometrial cancer. Gynecol. Oncol. 98(2), 299-303 (2005).
81. Mantovani G, Proto E, Massa E et al. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a Phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int. J. Oncol. 20(2), 419-427 (2002).
82. Kwok TT, Sutherland RM. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br. J. Cancer 64(2), 251-254 (1991).
83. Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol. Oncol. 73(3), 461-463 (1999).
84. Quino-Parsons C, Lim P, Wong F, Mildenberger M. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1A and 1B endometrial adenocarcinoma: treatment implications. Gynecol. Oncol. 71(1), 83-86 (1998).
85. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am. J. Surg. Pathol. 24(6), 797-806 (2000).
86. Vandenput I, Van CB, Capoen A et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br. J. Cancer 101(2), 244-249 (2009).
87. Despierre E, Moerman P, Vergote I, Amant F. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? Int. J. Gynecol. Cancer 16, S273-S277 (2006).